JP2016522178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522178A5 JP2016522178A5 JP2016509119A JP2016509119A JP2016522178A5 JP 2016522178 A5 JP2016522178 A5 JP 2016522178A5 JP 2016509119 A JP2016509119 A JP 2016509119A JP 2016509119 A JP2016509119 A JP 2016509119A JP 2016522178 A5 JP2016522178 A5 JP 2016522178A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- angiotensin
- peptide
- muscular dystrophy
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361813929P | 2013-04-19 | 2013-04-19 | |
| US61/813,929 | 2013-04-19 | ||
| US201361818307P | 2013-05-01 | 2013-05-01 | |
| US61/818,307 | 2013-05-01 | ||
| PCT/US2014/034615 WO2014189634A1 (en) | 2013-04-19 | 2014-04-18 | Angiotensins in muscular dystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016522178A JP2016522178A (ja) | 2016-07-28 |
| JP2016522178A5 true JP2016522178A5 (enExample) | 2017-05-25 |
Family
ID=51933952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509119A Pending JP2016522178A (ja) | 2013-04-19 | 2014-04-18 | 筋ジストロフィーにおけるアンジオテンシン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160074464A1 (enExample) |
| EP (1) | EP2986341A4 (enExample) |
| JP (1) | JP2016522178A (enExample) |
| KR (1) | KR20160026855A (enExample) |
| CN (1) | CN105636645A (enExample) |
| AU (1) | AU2014269028A1 (enExample) |
| BR (1) | BR112015026286A2 (enExample) |
| CA (1) | CA2909002A1 (enExample) |
| MX (1) | MX2015014668A (enExample) |
| RU (1) | RU2015141336A (enExample) |
| WO (1) | WO2014189634A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016152088A (ru) | 2014-07-17 | 2018-08-21 | Юниверсити Оф Саузерн Калифорния | Способы, соединения и композиции для лечения заболеваний опорно-двигательного аппарата |
| US10973869B2 (en) | 2017-05-17 | 2021-04-13 | Constant Therapeutics Llc | Methods of treating cardiomyopathy associated with genetic disorders |
| KR102885525B1 (ko) * | 2018-11-06 | 2025-11-13 | 엣지와이즈 테라퓨틱스, 인크. | 피리다지논 화합물 및 이의 용도 |
| SMT202300355T1 (it) | 2018-11-06 | 2024-01-10 | Edgewise Therapeutics Inc | Composti di piridazinone e loro usi |
| WO2020097258A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| EP4473968A3 (en) | 2020-05-13 | 2025-03-26 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN118680926B (zh) * | 2024-07-30 | 2024-12-20 | 北京市糖尿病研究所(北京市糖尿病防治办公室) | Mas受体激动剂在制备预防或治疗多囊卵巢综合征的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| BRPI0806230A2 (pt) * | 2007-01-26 | 2021-05-25 | Universidade Federal De Minas Gerais - Ufmg | composições farmacêuticas, método para tratar a disfunção erétil e método para restaurar a capacidade de ereção |
| ES2393455T3 (es) * | 2008-09-12 | 2012-12-21 | Charité-Universitátsmedizin Berlin (Charité) | Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas |
| US9186295B2 (en) * | 2011-10-25 | 2015-11-17 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| BR132012028005E2 (pt) * | 2012-10-31 | 2014-11-18 | Univ Minas Gerais | Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares. |
-
2014
- 2014-04-18 CN CN201480034275.5A patent/CN105636645A/zh active Pending
- 2014-04-18 AU AU2014269028A patent/AU2014269028A1/en not_active Abandoned
- 2014-04-18 KR KR1020157032700A patent/KR20160026855A/ko not_active Withdrawn
- 2014-04-18 RU RU2015141336A patent/RU2015141336A/ru not_active Application Discontinuation
- 2014-04-18 MX MX2015014668A patent/MX2015014668A/es unknown
- 2014-04-18 WO PCT/US2014/034615 patent/WO2014189634A1/en not_active Ceased
- 2014-04-18 BR BR112015026286A patent/BR112015026286A2/pt not_active Application Discontinuation
- 2014-04-18 CA CA2909002A patent/CA2909002A1/en not_active Abandoned
- 2014-04-18 US US14/785,538 patent/US20160074464A1/en not_active Abandoned
- 2014-04-18 EP EP14800597.8A patent/EP2986341A4/en not_active Withdrawn
- 2014-04-18 JP JP2016509119A patent/JP2016522178A/ja active Pending
-
2017
- 2017-09-05 US US15/695,731 patent/US20180221433A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517489A5 (enExample) | ||
| JP2009511579A5 (enExample) | ||
| RU2015141336A (ru) | Ангиотензины при мышечной дистрофии | |
| JP2014527040A5 (enExample) | ||
| JP2016534153A5 (enExample) | ||
| JP2018527000A5 (enExample) | ||
| JP5255456B2 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
| JP2013520405A5 (enExample) | ||
| JP2019507781A5 (enExample) | ||
| JP2019526556A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2017535547A5 (enExample) | ||
| JP2016506914A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| BR112014015142A2 (pt) | di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios | |
| JP2013544887A5 (enExample) | ||
| JP2019521647A5 (enExample) | ||
| JP2022505585A5 (enExample) | ||
| CL2017002987A1 (es) | Derivado de urea o sal farmacologicamente aceptable del mismo | |
| JP2011528332A5 (enExample) | ||
| JP2013533287A5 (enExample) | ||
| JP2014534956A5 (enExample) | ||
| JP2019529541A5 (enExample) | ||
| JP2017160178A5 (enExample) | ||
| FI3712264T3 (fi) | Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon |